DAS European Course in Pharmaceutical Medicine
MAS in Medicines Development
2017–2019
Table of Contents

Mission 4
Unique programme features 4
Learning outcomes 4
Pharmaceutical medicine 4
Syllabus: IMI PharmaTrain 4
Target audience 4
Admission criteria 5
Teaching faculty 5
Diploma Course Programme 5
Course dates 5
State-of-the-art lectures: Therapeutic areas and pharmacotherapy 12
Continuing education series “frontiers in drug development” 12
Course documents and learning methods 12
Final Examination 13
Master Programme 14
University network 15
Organisers 16
Registration Fee 16
University of Basel 17
Registration 17
Course venue 17
ECPM alumni 18
Advisory board 18

Under the auspices of
EUCOR the European Campus
IFAPP, International Federation of Associations of Pharmaceutical Medicine
Accredited by SwAPP/ SGPM
Recognised as PharmaTrain Centre of Excellence

Cover Photo: Drosera known as sundew, used as herbal remedy for dry cough, bronchitis and asthma
The European Center of Pharmaceutical Medicine (ECPM) is dedicated to be the leading university institute for medicines and drug development in Europe. ECPM was founded in 1991 to cover the training needs of specialists working in drug development. We offer a range of different training programmes to provide a holistic understanding of the drug, medicines or device development process from discovery to the benefit of patients including key concepts in clinical trials, regulatory science and marketing.

The ECPM Diploma Course (ECPM Course) in Pharmaceutical Medicine represents our core of the postgraduate training platform and offers a modular extension with single modules to achieve a Master of Advanced Studies in Medicines Development. The programmes are targeted at representatives from industry, service industry, academic and government decision- and policy-makers who already have a good grounding in the basics and will benefit from a more in-depth, comprehensive and systematic immersion into modern medical product and device development, regulation and market introduction.

ECPM belongs to the department of public health of the medical faculty at the University of Basel and operates with partners worldwide. The ECPM is accredited as IMI PharmaTrain Centre of Excellence and acknowledged by the International Federation of Associations of Pharmaceutical Physicians (IFAPP).

Participation in the ECPM training programmes provide the opportunity to integrate work and education, to discuss with experts face-to-face or online, to gain in-depth knowledge and enhance your expertise while building a professional network, and to put this into perspective with your own career plan.

An international faculty of experts from academia, pharmaceutical and biotechnology companies and regulatory authorities carry the teaching responsibility.

We cordially invite you to participate in the ECPM course.

Invitation
Deepen your expert knowledge
Take your skills to the next level.

Mission
Our mission is to provide the best international training platform to provide and enhance the knowledge, expertise and skills needed to perform modern discovery, development, regulation and marketing of medical products. An outstanding faculty teaches integrating cutting-edge concepts and best practices to enable the development of efficient, economical, high quality and safe medical products for the benefit of the patients and the society. ECPM is constantly innovating to offer Swiss excellence with a global perspective.

Unique programme features
- Deepen your knowledge in the essentials of the medical product lifecycle – from molecule to the marketplace
- Understand the trends in global pharmaceutical development and health care environment
- Expose yourself to new innovative methods, tools and strategies and apply them in your daily work
- Become a leader and integrator for medical product development
- Create a global professional network.
- Enhance your CV by acquiring a Diploma of Advanced Studies (DAS) in Pharmaceutical Medicine and take it to the next step of a Master of Advanced Studies (MAS) in Medicines Development
- Get a Swiss speciality recognition for MDs or SwAPP diploma
- Prepare for the next career step

Learning outcomes
On successful completion of this course in pharmaceutical medicine students should be able to demonstrate an understanding/knowledge of the following:
- the process of drug development and how to incorporate and apply the latest innovative bio-pharmaceutical development strategies, methodologies and tools
- the principal steps in drug discovery, target identification and non-clinical research
- the pertinent issues involved in the undertaking of clinical research and development
- the regulation of medicines in the various global markets, including ethical and legal provisions
- the management of drug safety issues pre-and post-marketing authorisation
- the management of all lifecycle activities (regulatory and marketing) of a medicinal product
- The principles of health economics and their application in the development and marketing of medicinal products

Pharmaceutical medicine
“Pharmaceutical Medicine is the scientific discipline for the discovery, development, evaluation, registration, monitoring and medical marketing of medicines for the benefit of the patients” (IFAPP)

Syllabus: IMI PharmaTrain
The course programme covers all aspects of pharmaceutical medicine and drug development sciences with an international scope as defined by the PharmaTrain syllabus. This includes the discovery and development of new medicines, biopharmaceutical sciences, clinical pharmacology and trial methodology, good clinical practice and ethics, pharmacovigilance and epidemiology, biostatistics, regulatory affairs, health economics, project management, marketing and new therapeutic approaches.
For details please see page 15 or www.pharmatrain.eu or www.ecpm.ch/teachingprinciple

Target audience
This course is targeted at participants from the industry, service industry, academic and government decision- and policy-makers who have a good grounding in the basics and will benefit from a more in-depth, comprehensive and systematic immersion into modern medical product development, regulation and market introduction.

Dr. Girish Naik, ECPM
Diploma Student, Trainee at Dana Farber cancer Institute, Harvard Medical School, USA
“The ECPM course no doubt will produce the future leaders of drug development”
Admission criteria

In order to enroll in the ECPM diploma course, applicants must have a higher university degree, such as a Master’s, MD, PharmD or PhD and a primary interest in medical product discovery, development, regulation and health care system. Applications sur dossier are possible on an individual basis. The programme is particularly aimed at professionals who are involved in the medical product development process and have at least 2 years of working experience.

Teaching faculty

The ECPM teaching faculty consists of about 200 international experts in regulatory sciences, medical product discovery and development, product evaluation and business practices. Lecturers and tutors will be drawn from academia, regulatory agencies (such as EMA, FDA and local agencies), pharmaceutical, diagnostic and biotechnology industry, coverage and reimbursement entities, professional societies and national institutes.

Diploma Course Programme

The ECPM course programme consists of 24 face to face teaching days divided into six modules over a period of two years (eight hours per day, each lesson 45–60 minutes), including team involvement in mentored, case-oriented breakout sessions. In addition, approximately eight hours distance learning per module is required in order to prepare for the case studies. All lectures are recorded and the videos are available on the ECPM mediathek for course participants.

Course dates

<table>
<thead>
<tr>
<th>Module</th>
<th>Course Title</th>
<th>Dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Module 2</td>
<td>From Non-Clinical Testing to First-in-Humans</td>
<td>05.02. – 08.02.2018</td>
</tr>
<tr>
<td>Module 3</td>
<td>Planning, Collecting and Managing Clinical Data</td>
<td>25.06. – 28.06.2018</td>
</tr>
<tr>
<td>Module 4</td>
<td>Clinical and Safety Data Evaluation and Biostatistics</td>
<td>03.09. – 06.09.2018</td>
</tr>
<tr>
<td>Module 5</td>
<td>Global Registration and Approval Process</td>
<td>04.02. – 07.02.2019</td>
</tr>
<tr>
<td>Module 6</td>
<td>Integrated Product Development, Healthcare Marketplace and Marketing</td>
<td>24.06. – 27.06.2019</td>
</tr>
<tr>
<td>Final Examination</td>
<td>Multiple choice</td>
<td>20.08.2019</td>
</tr>
<tr>
<td></td>
<td>Oral / essay</td>
<td>20.08.2019 or 10.09.2019</td>
</tr>
</tbody>
</table>

Employees in pharmaceutical industry

(2012)

Europe 725’000
Worldwide 4.4 Mio
From molecule to marketplace
Cutting edge principles to bridge your knowledge and work experience

Global Drug Development and Pharmaceutical Business Environment

September 4 – September 7, 2017

Content

Key topics
• Discovering, modifying, assessing and patenting new chemical and biological compounds
• System biology and principles of translational research
• Target identification and validation
• Introduction in the drug development process and the health care environment
• Drug development for special populations
• Project and portfolio management techniques

Learning outcomes
At the end of this module the student should be able to outline the:
1. Principal discovery and validation steps in drug development
2. The elements, functions and the management involved in the translational research and integrated development of a new drug
3. Principles of patenting new chemical compounds

Dr. Patricia Evans,
Teaching Faculty, Strategic Consultant, former partner at Covalence Capital Management, USA

“ECPM is ideal for professionals moving up in their organizations to learn the entire drug development process”
February 5 – February 8, 2018

From Non-Clinical Testing to First-in-Human

Content
Prioritising areas of therapeutic interest and target product profile. Principles for target identification, understanding of combinatorial chemistry and drugability of new compounds. Exploring possible new drugs by means of preclinical safety and efficacy testing. The choice and the predictive value of animal testing for toxicity data as well as the principles of ADME, possibilities and opportunities of computer assisted modelling on the way to proof of concept. Procedures and databases for pharmaco-vigilance and pharmacoepidemiology surveillance. Pharmaceutical engineering and choice of formulation.

Key topics
• Non-clinical testing for chemical and biological compounds, including pharmacology (ADME) and toxicology
• Development, testing and formulation of chemical and biological compounds
• Non-clinical testing requirements prior to First-in-Human studies
• Molecular and cellular basis of toxicological reactions
• Genetic and genomic factors in drug development and drug response
• Transition from non-clinical to First-in-Human studies
• Clinical pharmacology and application to clinical development

Learning outcomes
At the end of this Module the student should be able to describe the:
1. Value of non-clinical testing programmes and their integration into the overall drug development plan
2. Steps in the pharmaceutical development of a drug substance
3. Principles of clinical pharmacology and their application to clinical development
4. Requirements, planning and regulations of non-clinical and First-in-Human studies

Maya Farah, Diploma Course Student, Pharmacist, SYR
“As a pharmacist who worked in pharmaceutical companies, the high quality education of this course has broadened my understanding of drug development and provided me with well-rounded knowledge of its entire process.”
Modul 3

Content
The planning, the choice of different trial designs, the randomisation modes and the choice of endpoints are discussed. The different aspects of the conduct of a trial, i.e. study monitoring, principles of good clinical practice (GCP), adverse event monitoring (risk/benefit assessment) and data management are demonstrated. A basic introduction to biostatistics is given.

Key topics
- Early studies in patients: dose-finding / proof of mechanism studies
- Confirmatory clinical development plan
- Different types of clinical studies, including placebo controlled studies
- Planning and managing clinical trials
- Planning of clinical trial supplies for test substance and comparators
- Legislative requirements and Good Clinical Practice (GCP) in the clinical trial process
- Investigator and site recruitment, investigative site management and conflict resolution
- Statistical considerations in the design of clinical trial protocols and analysis of clinical trial data
- Procedures for clinical trial data collection and data management

Learning outcomes
At the end of this module the student should be able to outline the:
1. Management of early studies in patients and their impact on the drug development plan
2. Design of various types of clinical studies and statistical methods used
3. The confirmatory clinical development plan including the role of relevant study committees
4. Key issues involved in the conduct of a clinical study in terms of Good clinical Practice (GCP)
Content
The different tests and methods of biostatistics are discussed. The application of different trial designs is simulated, within-trial decisions, data management, extraction, manipulation and storage of data.

Key topics
• Development of a clinical trial protocol and the investigator drug brochure (IDB)
• Quality management issues in clinical trials
• Legal and ethical provisions for protection of clinical trial subjects
• Statistical methods used in clinical research
• Collection and evaluation of adverse event data in clinical trials
• Drug safety monitoring board and other relevant study committees
• Evaluation and interpretation of clinical trial results

Learning outcomes
At the end of this Module the student should be able to describe the:
1. Development of a clinical trial protocol and the role of the investigator drug brochure (IDB)
2. Principles and practical relevance of ethical and legal issues in biomedical research
3. Evaluation and interpretation of clinical trial results
4. Main statistical methods used in clinical data analysis
5. Collection and evaluation of adverse event data in clinical trials

September 3 – September 6, 2018
Clinical and Safety Data Evaluation and Biostatistics

Professor Robert O’Neill, Teaching Faculty, former Director Office of Biostatistics FDA, USA

“ECPM continues to be a premier program for integrated knowledge on the life cycle of global pharmaceutical development and regulation”
Modul 5

February 4 – February 7, 2019

Global Registration and Approval Process

Content
Overview on mechanisms and regulatory management systems in Europe, the USA and Asia. Requirements of a regulatory application, documentation and collaboration between developers and regulators. Special regulatory procedures, strategies and crisis management.

Key topics
- Regulation of pre- and post-approval of medicines at EU and global level
- Regulatory activities within a pharmaceutical company
- Labelling requirements
- National and international bodies responsible for medicines regulation and their procedures
- Appeal and Referral
- Off-label/unlicensed use of medicines
- International Conference on Harmonisation (ICH)
- Common technical document (CTD)
- Special Interest Area Community (SIAC)
- Pharmacovigilance: Classification of adverse events/reactions
- Safety reporting requirements pre- and post-approval
- Benefit/risk assessment and pharmacoepidemiology throughout the lifecycle of a medicine

Learning outcomes
At the end of this module the student should be able to outline the:
1. General principles of medicines and medical devices regulation (both pre- and post-approval)
2. Principles and management of drug safety and pharmacovigilance
3. Role of pharmacoepidemiology in the lifecycle management of a medicine
Content
Principles of project and portfolio management, including aspects of planning, project evaluation and decision making. Management structure and organisation of clinical development. Team work and performance assessment. Interaction between project teams and business. How to place a new drug successfully into the market.

Key topics
• Principles and regulations of drug marketing
• Good Promotional Practice: ethical and legal principles pertaining to marketing activities
• Health economics and health technology assessment (HTA)
• Patient Organisations
• Life cycle management
• Strategic considerations of portfolio management

Learning outcomes
At the end of this Module the student should be able to describe the:
1. Principles and practice of the quality system of drug lifecycle activities
2. Ethical and legal principles of market introduction of a drug
3. Principles and practical application of health economics and health technology assessment (HTA) within the healthcare marketplace
State-of-the-art lectures: Therapeutic areas and pharmacotherapy

Content
Principles of physiology and clinical pharmacology of important diseases, state-of-the-art information on pharmacotherapy and new therapeutic approaches. These topics are intimately interwoven with pharmaceutical medicine and are distributed over the six course modules.

Possible Topics are:
• The Cardiovascular System
• The Respiratory System
• The Gastrointestinal System
• Genome Based Drug Discovery and Pharmacogenomics
• The Central Nervous System
• Metabolic Diseases: Link between Adipositas and Diabetes
• Immunopharmacology
• Antinfectives and Antivirals
• Treatments for Cancer
• Gene Therapy
• Pain Management

Continuing education series “frontiers in drug development”

The fourth day of every course module is open to alumni and other professionals who are looking for continuing education in this field. These seminars are dealing with current topics, new trends and developments in drug development science. They provide flexibility for introducing relevant topics into the curriculum and build a mandatory part of the diploma course.

Course documents and learning methods
You can choose to receive either a course file including a summary, a reference list and the slides of each lecture in paper or you will be able to download the teaching material on the first day of the course. Should the documents not be available prior to the module we will provide them once they are available.

The cost of the paper version is CHF 500 and the folder will be provided on the first day of each module.

All lectures are video recorded and can be viewed together with the PowerPoint slides on the protected ECPM website. These files can be viewed on computers, iPads, tablets and smart phones. Students are personally responsible for preparing for the final examination. The learning process of the course includes didactic teaching and places a great emphasis on interactive participation. Each module includes the following activities:

Lectures
State-of-the-art lectures and updates on important drug, diagnostic and therapeutic areas and issues, followed by in-depth discussions.

Case Studies
Participants work in small interdisciplinary teams on ‘real-life cases’. Problems are analysed and discussed together with faculty members. Participants try to reach a common strategy, which is then presented and defended in a round-table discussion. Three weeks prior to each module you will be able to download the documents and the background literature from our website in order to prepare yourself. We expect you to read the material in advance, in order to be able to actively discuss the problems.

Continuing Education Seminars – ‘Frontiers in Drug Development’
These seminars on day four of the course module are an integral and mandatory part of the ECPM course and in addition open to alumni and other professionals who are looking for continuing education in this field.

ECPM website / mediathek
Documents, glossary, videos and self-testing are available for course participants on the ECPM website. You need to log in under my ecpm.

The course language is English.
**Title system**

Modular training parallel to work.

---

**Final Examination**

The final examination is a closed book exam and will be performed on iPads onsite. The multiple choice examination (120 questions) will take place on August 20, 2019 from 9:00 to 13:00. Oral/essay examination can either be taken on the same day in the afternoon or on September 10, 2019.

**Certificate of Advanced Studies in Pharmaceutical Medicine (CAS): 20 ECTS**

Successful completion of the two-years course cycle and passing of the final multiple choice examination will lead to a Certificate of Advanced Studies (CAS) in Pharmaceutical Medicine by the University of Basel.

**Diploma of Advanced Studies in Pharmaceutical Medicine (DAS): 30 ECTS**

Successful completion of the two-years course cycle and passing the final examination consisting of the multiple choice test, an oral and an essay writing will lead to a Diploma of Advanced Studies (DAS) in Pharmaceutical Medicine by the University of Basel.

**Master of Advanced Studies in Medicines Development (MAS): 60 ECTS**

Complementing the DAS with elective courses (20 ECTS) either from the ECPM training platform or the PharmaTrain partner Universities and writing a master thesis will lead to a Master of Advanced Studies (MAS) in Medicines Development by the University of Basel.

**Specialist in Pharmaceutical Medicine FMH or SwAPP Diploma**

For MDs, the Diploma of Advanced Studies in Pharmaceutical Medicine covers the theoretical part required for the FMH (Swiss Association of Medical Doctors) speciality title in pharmaceutical medicine as defined by the Swiss Association of Pharmaceutical Physicians (www.sgpm.ch). The SwAPP (Swiss Association of Pharmaceutical Professionals) offers an equivalent title for people holding an MSc and/or PhD (www.swapp.ch).
MAS in Medicines Development (MMD)
Study in an international network.

**Master programme**

Deepen your knowledge and expertise in modern medical product development, regulation and market introduction by adding your personalised modules and a master thesis to achieve a Master of Advanced Studies in Medicines Development from the University of Basel. This offers the possibility to intensify certain aspects or to fill gaps in your portfolio.

The six modules and the successful examination of the diploma course (30 ECTS) form the compulsory part of the master programme. The remaining master modules (20 ECTS) can be chosen and booked à la carte (please see CPD list on www.ecpm.ch. Since the programme is completed in parallel to work, a study duration of maximum 5 years is possible. Participants will be registered as students of the University of Basel.

The third part to achieve the MAS is the writing and the defence of the master thesis. The topic and the tutor will be defined and agreed upon with the course directorate. This will provide the final 10 ECTS to be awarded a Master of Advanced Studies in Medicines Development by the University of Basel.

The MAS is composed of three parts (60 ECTS):

**MAS**
- Master in Medicines Development 60 ECTS
- Diploma in Pharmaceutical Medicine 30 ECTS
- Certificate in Pharmaceutical Medicine 20 ECTS

**MAS**
- Master Thesis 10 ECTS
- Master Modules 20 ECTS
- Individual Modules CPD = Continuing Professional Development
- Oral / Essay Exam 10 ECTS
- Diploma Modules (compulsory) incl MCQ Exam 20 ECTS

**CAS**
- Certificate in Pharmaceutical Medicine 20 ECTS

**DAS**
- Diploma in Pharmaceutical Medicine 30 ECTS

---

Graduates

**CAS**
- since 1991
- 1194

**DAS**
- since 2005
- 499

**MAS**
- since 2015
- 2

---

European Course in Pharmaceutical Medicine.
ECPM training platform and university network
CPD and Master Modules from the ECPM Training Platform

The master or individual modules can be chosen according to the interest and needs of the students. They can be taken either from our training platform (see list below) or from our partner universities, which offer training relevant to drug development sciences and the IMI PharmaTrain syllabus (www.pharmatrain.eu). Before enrolling in a course at another university with the intent of having this accredited towards your masters, we strongly recommend that you contact the course directorate to ensure that the courses will be accredited. Learning outcomes of the modules are assessed individually upon completion of each module to achieve the credit points. All courses can also be booked as single courses for your continuing professional education.

Please note that programmes and topics are subject to change and constantly expanded. Many modules are being planned and offered according to market need. Please see details in www.ecpm.ch/cpd/

University network

A consortium of 21 European universities, 15 pharmaceutical companies of the European Federation of Pharmaceutical Industries Association (EFPIA), 11 learned societies (associations and agencies), 3 advisors and the EU performed a project (2009–2014) under the public private partnership of the IMI (Innovative Medicines Initiative) concerned with education and training in medicines development. ECPM was the managing entity and the achievements of the project include: shared training syllabus, shared examination standards, mutual recognition of learning outcomes and credit points (see www.pharmatrain.eu).

ECPM has established an international network and collaboration with courses in drug development and regulatory sciences. Its partner courses at Peking University Research Institute and the University of San Francisco in Washington share the same teaching principles and quality label. This unique global collaboration offers the possibility to start training at one site and continue or successfully achieve the diploma at one of the sister courses in Basel, Beijing and Washington.

<table>
<thead>
<tr>
<th>Topic</th>
<th>Course Format</th>
<th>ECTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Communication and Presentation Skills</td>
<td>Onsite plus pre and post assignment</td>
<td>2</td>
</tr>
<tr>
<td>Ethics and Legal Aspects of Medicines Development</td>
<td>Onsite plus pre and post assignment</td>
<td>2</td>
</tr>
<tr>
<td>Follow-on drugs: Generic, Biosimilar and non-Biological Similar Medicinal Products at Semmelweis University, Budapest</td>
<td>Onsite plus pre and post assignment</td>
<td>3</td>
</tr>
<tr>
<td>Leadership and Business Development</td>
<td>Onsite plus pre and post assignment</td>
<td>3</td>
</tr>
<tr>
<td>Project Management in Medicines Development</td>
<td>Onsite plus pre and post assignment</td>
<td>4</td>
</tr>
<tr>
<td>Scientific Medical Writing</td>
<td>Onsite plus pre and post assignment</td>
<td>1</td>
</tr>
<tr>
<td>Study Trip on Different Health Care Systems</td>
<td>Onsite plus pre and post assignment</td>
<td>3</td>
</tr>
<tr>
<td>Summer Institute in Regulatory Science at the George Washington University, Washington</td>
<td>Onsite plus pre and post assignment</td>
<td>3</td>
</tr>
<tr>
<td>Health Economics</td>
<td>e-learning or onsite</td>
<td>1</td>
</tr>
<tr>
<td>Safety</td>
<td>e-learning</td>
<td>1</td>
</tr>
<tr>
<td>Personalised Healthcare</td>
<td>e-learning</td>
<td>1</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td></td>
<td><strong>24</strong></td>
</tr>
</tbody>
</table>

Pharmaceutical market

- USA 41%
- Europe 26.7%
- Africa, Asia and Australia 14.7%
- Japan 11.7%
- Latin America 5.9%

PD Dr. Detlef Niese, Teaching Faculty, former Head External Affairs at Novartis Pharma and associate professor at University of Bonn, DE

“Drug development is becoming increasingly complex. To cope with the challenge to develop innovative therapies and diagnostic tools highly skilled and trained specialists and executive managers are needed. ECPM is collaborating intensively with academic institutions, regulatory authorities, patient organisations and the research based pharmaceutical industry to offer tailor made education and training.”
**Organisers**

The ECPM course is organised by the European Center of Pharmaceutical Medicine, a university institute at the medical faculty of the University of Basel, Switzerland which is also a member of the Pharmacenter Basel (Center of Pharmaceutical Sciences, University of Basel). The ECPM course was established in 1991 in partnership with the EUCOR, European Confederation of the Upper Rhine Universities medical schools of the Universities of Basel, Freiburg i. Br. and Strasbourg and the pharmaceutical industry.

**Registration Fee**

The tuition fee for the entire diploma course amounts to CHF 14’750. A reduced fee of CHF 13’750 applies to continuing training centres and for companies who register more than 10 participants. The special fee for non-for profit organisations is CHF 9’000. The individual master modules differ in price and institution while the scientific guidance and defence of the master thesis at the University of Basel implies a fee of CHF 3’500.

The tuition fee includes matriculation at the University of Basel, online course material, access to the online mediathek, lunches, coffee breaks and welcome aperitif.

The entire tuition fee is payable on confirmation of attendance by June 30, 2017. The payment may be made in two instalments, first payment on June 30, 2017 and second payment on June 30, 2018.

In case of cancellation after June 30, 2017, the tuition fee less CHF 750.– for administrative expenses will be returned. There will be no refund on cancellations after this date.

Accommodation for the course modules is not included in the tuition fee and should hence be booked separately. We can offer a reduced rate for some hotels. Please contact ecpm@unibas.ch for more information.

---

<table>
<thead>
<tr>
<th>CPD</th>
<th>CAS</th>
<th>DAS</th>
<th>MAS</th>
<th>Swiss Specialist in PM or SwAPP Diploma</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 core modules in Pharmaceutical Medicine</td>
<td>14’750</td>
<td>14’750</td>
<td>14’750</td>
<td>14’750</td>
</tr>
<tr>
<td>Groups and training centres</td>
<td>13’750</td>
<td>13’750</td>
<td>13’750</td>
<td>13’750</td>
</tr>
<tr>
<td>Non for profit organisations</td>
<td>9’000</td>
<td>9’000</td>
<td>9’000</td>
<td>9’000</td>
</tr>
<tr>
<td>Printed course material</td>
<td>500</td>
<td>500</td>
<td>500</td>
<td>500</td>
</tr>
<tr>
<td>MCQ Examination</td>
<td>incl.</td>
<td>incl.</td>
<td>incl.</td>
<td>incl.</td>
</tr>
<tr>
<td>Oral/Essay Examination</td>
<td>na</td>
<td>750</td>
<td>750</td>
<td>750</td>
</tr>
<tr>
<td>Single or individual modules</td>
<td>750 – 3000</td>
<td>na</td>
<td>na</td>
<td>750 – 3000</td>
</tr>
<tr>
<td>Master thesis</td>
<td></td>
<td></td>
<td>3’500</td>
<td></td>
</tr>
<tr>
<td>total</td>
<td>750 – 3000</td>
<td>14’750</td>
<td>15’500</td>
<td>about 25’000 depending on choice of modules</td>
</tr>
</tbody>
</table>

Tuition fees in CHF / Prices 2017 (can be subject to change)
University of Basel

Grand tradition
Founded in 1460, Basel is Switzerland’s oldest university. Its students and teachers have included such great minds as the physician and alchemist Paracelsus, mathematicians Jakob Bernoulli and Leonhard Euler, and philosophers Friedrich Nietzsche and Karl Jaspers.

In the top ten
Leading higher-education rankings such as the “Academic Ranking of World Universities” place the University of Basel among the world’s 100 best universities. Within the German-speaking countries, it is one of the top ten in 2016.

Beacon for life sciences
Life Sciences are the main focal area at the University of Basel, closely linked with Basel’s status as a centre of pharmaceuticals and biotechnology and the home of the two large research based pharmaceutical companies Novartis and Roche.

Registration
Registrations are reviewed and will be confirmed on an ongoing basis. Deadline for application is March 31, 2017. As enrolment is limited, prospective participants are encouraged to apply well in advance. Registration can be done via the internet: www.ecpm.ch/application-diploma/

ECPM course participants will be registered as students at the University of Basel at no cost. To obtain the student card a separate form (requiring a printed photo) will be provided by the university. A strong command of English is necessary to comprehensively follow the course.

Applications together with a one two-page curriculum vitae and a copy of the University diploma (or a certified English or German translation) should be submitted to:

ECPM
Beatrice Schmid
Institute of Pharmaceutical Medicine
University of Basel
Klingelbergstrasse 61
CH-4056 Basel, Switzerland
Phone +41 61 207 1950
Fax +41 61 207 1948
E-mail ecpm@unibas.ch
Web page www.ecpm.ch

Course venue
Medical Faculty: Institute of Pathology,
University of Basel, Hebelstrasse/ Schöneinistrasse 40, Basel, Switzerland and
Department of Pharmaceutical Sciences.
Pharmacenter, University of Basel
Klingelbergstrasse 50, Basel, Switzerland

Bus to “Basler Kinderspital UKBB” from Basel SBB railway station and Badischer Bahnhof No 30

From Airport Basel-Mulhouse: Bus No 50 to Basel SBB railway station, then change to Bus No 30
Walking distance from Marktplatz: 15 minutes

Members of the Course Directorate from left:
Beatrice Schmid,
Thomas D. Szucs,
Annette Mollet,
Katja Suter
ECPM alumni

The ECPM alumni club is open to all participants who attended a full course cycle. The alumni are regularly informed about the ECPM activities and are invited to the continuing education seminars at a reduced fee. These events are accredited for continuing professional education.

Advisory board

Members of the Advisory Board
Academia
Dr. Ruth Amstein, Zurich Heart House
Dr. Gerd Antes, Albert-Ludwigs-University
Dr. Rolf Heusser, National Institute for Cancer Epidemiology and Registration (NICER), Zurich
Dr. Marius Kränzlin, University of Basel
Dr. Martin Liechti, University of Basel
Prof. Martin Schumacher, Albert-Ludwigs-University, Freiburg i.Br.

Pharma Industry
PD Dr. Patricia Blank, Roche Diagnostics
Dr. Martine Clozel, Actelion Pharmaceuticals Ltd.
Mr. Thomas Cueni, Interpharma
Dr. David Ebsworth, former Vifor Pharma AG
Dr. Djordje Filipovic, Novartis Pharma AG
Mr. Manfred Heinzer, Roche Pharma (Schweiz) AG
Dr. Toni Man, Novartis Pharma AG
Dr. Oliver Nayler, Actelion Pharmaceuticals Ltd.
Dr. Detlef Niße, former Novartis Pharma AG

Regulator
Dr. Jörg Schläpfer, Swissmedic
Educating
Talents
since 1460.

University of Basel
ECPM
Institute of Pharmaceutical Medicine
Klingelbergstrasse 61
4056 Basel
Switzerland

www.ecpm.ch